The Swiss pharma is one step closer to bringing Lutathera into the front-line setting, with data from the Phase III NETTER-2 study showing that the radiotherapy met its primary endpoint.
https://www.pharmalive.com/wp-content/uploads/2023/09/Novartis-California.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-09-26 08:45:082023-09-26 09:03:48Novartis’ Lutathera clears Phase III as frontline treatment for rare neuroendocrine cancer
